Role of miRNA-145, 148, and 185 and Stem Cells in Prostate Cancer.
PCSCs
cell proliferation
miRNAs
prostate cancer
stem cells
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
30 Jan 2022
30 Jan 2022
Historique:
received:
29
11
2021
revised:
11
01
2022
accepted:
29
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
15
3
2022
Statut:
epublish
Résumé
MicroRNAs (miRNAs) are small non-coding RNA molecules that play a role in cancer linked to the regulation of important cellular processes and pathways involving tumorigenesis, cell proliferation, differentiation, and apoptosis. A lot of human miRNA sequences have been identified which are linked to cancer pathogenesis. MicroRNAs, in prostate cancer (PC), play a relevant role as biomarkers, show a specific profile, and have been used as therapeutic targets. Prostate cancer (PC) is the most frequently diagnosed cancer in men. Clinical diagnoses among the gold standards for PC diagnosis and monitoring are prostate-specific antigen (PSA) testing, digital rectal examination, and prostate needle biopsies. PSA screening still has a large grey area of patients, which leads to overdiagnosis. Therefore, new biomarkers are needed to improve existing diagnostic tools. The miRNA expression profiles from tumour versus normal tissues are helpful and exhibit significant differences not only between cancerous and non-cancerous tissues, but also between different cancer types and subtypes. In this review, we focus on the role of miRNAs-145, 148, and 185 and their correlation with stem cells in prostate cancer pathogenesis. MiR-145, by modulating multiple oncogenes, regulates different cellular processes in PC, which are involved in the transition from localised to metastatic disease. MiR-148 is downregulated in high-grade tumours, suggesting that the miR-148-3 family might act as tumour suppressors in PC as a potential biomarker for detecting this disease. MiR-185 regulation is still unclear in being able to regulate tumour processes in PC. Nevertheless, other authors confirm the role of this miRNA as a tumour suppressor, suggesting its potential use as a suitable biomarker in disease prognosis. These three miRNAs are all involved in the regulation of prostate cancer stem cell behaviour (PCSCs). Within this contest, PCSCs are often involved in the onset of chemo-resistance in PC, therefore strategies for targeting this subset of cells are strongly required to control the disease. Hence, the relationship between these two players is interesting and important in prostate cancer pathogenesis and in PCSC stemness regulation, in the attempt to pave the way for novel therapeutic targets in prostate cancer.
Identifiants
pubmed: 35163550
pii: ijms23031626
doi: 10.3390/ijms23031626
pmc: PMC8835890
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN145 microRNA, human
0
MIRN148 microRNA, human
0
MIRN185 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
J Pathol. 2009 Jan;217(2):299-306
pubmed: 19040209
Oncotarget. 2016 May 24;7(21):30760-71
pubmed: 27120795
PLoS One. 2013 Jun 07;8(6):e64795
pubmed: 23762257
Cancer Cell Int. 2007 Mar 15;7:2
pubmed: 17362521
BMC Urol. 2020 May 4;20(1):49
pubmed: 32366240
J Cell Physiol. 2009 Aug;220(2):485-91
pubmed: 19391107
Annu Rev Pathol. 2014;9:287-314
pubmed: 24079833
Int J Mol Sci. 2016 Mar 22;17(3):421
pubmed: 27011184
Mol Cancer Res. 2014 Feb;12(2):250-63
pubmed: 24337069
Mol Med Rep. 2019 Sep;20(3):2774-2782
pubmed: 31524259
Biosci Rep. 2015 Apr 28;35(2):
pubmed: 25797907
Genet Mol Biol. 2020 Mar 06;43(1):e20180330
pubmed: 32154827
Biol Rev Camb Philos Soc. 2020 Aug;95(4):911-935
pubmed: 32073216
Carcinogenesis. 2015 Aug;36(8):858-66
pubmed: 25969144
Cancer Res. 2008 Aug 1;68(15):6162-70
pubmed: 18676839
Cells. 2019 Aug 05;8(8):
pubmed: 31530793
Int J Cancer. 2012 Aug 1;131(3):652-61
pubmed: 22052531
Prostate. 2017 Jul;77(10):1167-1175
pubmed: 28617988
Prostate. 2014 Sep;74(13):1320-34
pubmed: 25053345
Int J Mol Sci. 2013 Mar 04;14(3):5239-49
pubmed: 23459235
Crit Rev Biochem Mol Biol. 2016 May-Jun;51(3):121-34
pubmed: 26628006
Int J Cancer. 2012 Feb 1;130(3):611-21
pubmed: 21400514
Int J Cancer. 2015 Feb 15;136(4):875-9
pubmed: 24976077
Cells. 2021 Jul 11;10(7):
pubmed: 34359925
Prostate Cancer Prostatic Dis. 2010 Dec;13(4):356-61
pubmed: 20820187
Cancer Drug Resist. 2021;4:684-709
pubmed: 34322664
Mol Biol Rep. 2021 Jul;48(7):5531-5539
pubmed: 34318435
J Urol. 2014 Feb;191(2):487-92
pubmed: 23911636
PLoS One. 2014 Jun 26;9(6):e98675
pubmed: 24967583
J Cell Biochem. 2019 Oct;120(10):17228-17239
pubmed: 31104329
Prostate. 1987;11(4):327-37
pubmed: 2446300
Adv Exp Med Biol. 2013;786:329-51
pubmed: 23696365
Exp Biol Med (Maywood). 2015 Aug;240(8):1071-8
pubmed: 25966983
RNA Biol. 2012 Jun;9(6):703-19
pubmed: 22664915
Cell. 2009 May 15;137(4):647-58
pubmed: 19409607
Oncogene. 2008 Mar 13;27(12):1788-93
pubmed: 17891175
Cell Death Differ. 2010 Feb;17(2):246-54
pubmed: 19730444
Int J Cancer. 2011 Feb 1;128(3):608-16
pubmed: 20473869
Stem Cells Int. 2018 Feb 28;2018:5416923
pubmed: 29681949
Oncogene. 2016 May 5;35(18):2345-56
pubmed: 26364608
Cancer Gene Ther. 2008 Jun;15(6):341-55
pubmed: 18369380
Oncol Rep. 2012 Nov;28(5):1831-7
pubmed: 22948942
Bioengineered. 2021 Dec;12(1):3240-3251
pubmed: 34238129
Prostate. 2012 Sep 15;72(13):1469-77
pubmed: 22298119
Avicenna J Med Biotechnol. 2009 Jul;1(2):55-70
pubmed: 23407615
Medicina (Kaunas). 2019 Sep 03;55(9):
pubmed: 31484346
J Cancer. 2013 May 09;4(5):350-7
pubmed: 23781281
Cancer Res. 2011 Mar 1;71(5):1956-67
pubmed: 21343391
Clin Cancer Res. 2015 Nov 1;21(21):4970-84
pubmed: 26089375
Gene. 2020 Oct 20;758:144963
pubmed: 32683077
PLoS One. 2016 Sep 21;11(9):e0161491
pubmed: 27655328
Oncotarget. 2015 Dec 22;6(41):43819-30
pubmed: 26540468
J Am Soc Nephrol. 2017 Dec;28(12):3579-3589
pubmed: 28814511
Cells. 2020 Aug 12;9(8):
pubmed: 32806709
Cancer Res. 2007 Jul 1;67(13):6130-5
pubmed: 17616669
J Oral Pathol Med. 2004 Jul;33(6):317-22
pubmed: 15200478
Curr Opin Genet Dev. 2013 Feb;23(1):3-11
pubmed: 23465882
Br J Cancer. 2017 Jul 25;117(3):409-420
pubmed: 28641312
Prostate. 2019 Jun;79(9):961-968
pubmed: 30958910
Onco Targets Ther. 2020 Aug 13;13:8079-8094
pubmed: 32904700
Mol Cell Biochem. 2013 May;377(1-2):121-30
pubmed: 23417242
Adv Exp Med Biol. 2010;695:155-68
pubmed: 21222205
Cancer Sci. 2006 Sep;97(9):821-8
pubmed: 16822297
J Cell Biochem. 2018 Mar;119(3):2763-2786
pubmed: 29095529
Oncol Lett. 2021 Nov;22(5):805
pubmed: 34630712
Biomed Res Int. 2013;2013:107954
pubmed: 23936768
Oncol Lett. 2018 May;15(5):8157-8164
pubmed: 29849810
Interface Focus. 2014 Jun 6;4(3):20130075
pubmed: 24904738
J Cancer Res Clin Oncol. 1997;123(5):280-5
pubmed: 9201251
Am J Cancer Res. 2012;2(6):620-57
pubmed: 23226612
Urol Oncol. 2013 Aug;31(6):796-801
pubmed: 21880514
Br J Cancer. 2013 Jun 25;108(12):2573-81
pubmed: 23703249
Endocrinology. 2005 Jan;146(1):13-8
pubmed: 15471963
Stem Cells. 2008 Mar;26(3):600-10
pubmed: 18055450
J Urol. 2011 Mar;185(3):1118-22
pubmed: 21255804
Int J Mol Sci. 2019 Oct 14;20(20):
pubmed: 31615086
PLoS One. 2013 May 21;8(5):e63563
pubmed: 23704919
Development. 2017 Apr 15;144(8):1382-1398
pubmed: 28400434
PLoS One. 2013 Aug 09;8(8):e70987
pubmed: 23951060